Hennion & Walsh Asset Management Inc. Sells 7,169 Shares of Catalent, Inc. (NYSE:CTLT)

Hennion & Walsh Asset Management Inc. lessened its stake in shares of Catalent, Inc. (NYSE:CTLT) by 43.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,467 shares of the company’s stock after selling 7,169 shares during the quarter. Hennion & Walsh Asset Management Inc.’s holdings in Catalent were worth $534,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in CTLT. Gladius Capital Management LP acquired a new stake in Catalent in the third quarter valued at approximately $28,000. GAMMA Investing LLC acquired a new stake in Catalent in the 4th quarter valued at $33,000. Rakuten Securities Inc. bought a new stake in Catalent during the 4th quarter valued at $46,000. Federated Hermes Inc. acquired a new position in Catalent during the fourth quarter worth $46,000. Finally, Mather Group LLC. bought a new position in shares of Catalent in the first quarter valued at $52,000.

Analyst Ratings Changes

CTLT has been the topic of a number of analyst reports. Stephens restated an “equal weight” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. StockNews.com initiated coverage on Catalent in a research note on Sunday. They issued a “sell” rating for the company. Finally, Barclays lifted their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $55.65.

Insider Activity

In related news, insider Ricky Hopson sold 1,401 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the transaction, the insider now owns 20,617 shares in the company, valued at $1,118,678.42. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.31% of the company’s stock.

Catalent Stock Up 0.1 %

CTLT stock opened at $56.20 on Wednesday. The stock has a market cap of $10.17 billion, a P/E ratio of -9.21 and a beta of 1.16. The company has a current ratio of 2.51, a quick ratio of 1.77 and a debt-to-equity ratio of 1.37. The stock’s fifty day simple moving average is $55.57 and its two-hundred day simple moving average is $54.17. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $60.20.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Analysts expect that Catalent, Inc. will post -0.17 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.